Free Trial
→ U.S. Government: “this could save civilization.” (From Porter & Company) (Ad)

Shionogi & Co., Ltd. Q1 2025 Earnings Report

Shionogi & Co., Ltd. logo
$6.87 -0.09 (-1.29%)
(As of 05:50 PM ET)
Earnings History

Shionogi & Co., Ltd. Earnings Headlines

Shionogi's Xocova effective in preventing symptomatic COVID-19: study
October 30, 2024 | msn.com
Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission
October 29, 2024 | msn.com
U.S. Government: “this could save civilization.”
Experts indicate that ChatGPT alone consumes up to 17,000 times more electricity than the average U.S. household uses in a single day. And with companies like Google and Microsoft implementing AI into everything we do, that energy consumption is only going to exponentially increase. Thing is, outside of a small group of elite investors, nobody has connected the dots on how this military contractor could be the most important company in the AI boom.
December 18, 2024 | Porter & Company (Ad)
Jefferies Sticks to Its Hold Rating for Shionogi & Co (SGIOF)
October 28, 2024 | markets.businessinsider.com
Shionogi & Co., Ltd. (4507.T)
October 27, 2024 | finance.yahoo.com
SGIOF Shionogi & Co., Ltd.
September 25, 2024 | seekingalpha.com
See More Shionogi & Co., Ltd. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. and other key companies, straight to your email.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

View Shionogi & Co., Ltd. Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles
Upcoming Earnings